Abstract
299 outpatients were included in this open multi-centre 3-week study of the efficacy and safety of sustained-release tramadol (CAS 27203-92-5, Tramal retard), in various pain conditions. Tramadol was administered 2 x 100 mg daily without prior introduction using an immediate release formula of the drug or titration of the dose. Of the 299 outpatients that were the subject of this study, 177 patients suffered from musculoskeletal pain, 58 from malignant pain and 44 suffered from postoperative pain, all treated by a total of 57 medical doctors of various profiles. The remainder of 20 patients suffered from pain conditions falling out of the aforementioned three categories. 274 (83%) of the patients were administered a daily dose of 200 mg tramadol. A satisfactory analgesic effect was found in 97% of all 299 patients. A good or very good quality of analgesia was present in 76.4% of the patients. Side effects were noted in 89 (29.8%) patients. A significant increase of the quality of life (responders) was registered in 49.1% of all patients. 200 mg daily dosage of sustained release tramadol could be a good option for pain control in musculoskeletal and postoperative pain conditions, especially when non-steroidal anti-inflammatory drugs are contraindicated.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
